Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 19, 2025
Emerging Company Profile
Trio: Introducing two new types of dual-targeting antibodies for cancer
San Francisco Bay Area biotech has two antibody platforms designed to improve on the potency and safety of bispecifics
BioCentury | Feb 11, 2025
Data Byte
FDA’s new and supplemental approvals in January
Vertex’s Nav1.8 inhibitor, Axsome’s acute migraine therapy and Daiichi-AZ’s two ADCs for breast cancer among the month’s approvals
BioCentury | Feb 1, 2025
Data Byte
Safety of Alzheimer’s therapy again under scrutiny at EMA’s CHMP
Plus: Pfizer’s Tivdak gets CHMP nod, as Daiichi’s Dato-Dxd receives positive opinion in one indication, gets withdrawn in another
BioCentury | Jan 8, 2025
Data Byte
Seven PDUFA dates on FDA’s January agenda
Decisions include Ozempic for CKD, a non-opioid painkiller, AZ-Daiichi’s TROP2 ADC, and an allogeneic T cell therapy
BioCentury | Dec 11, 2024
Data Byte
November’s FDA approvals include Autolus’ CD19 CAR T
Plus: BridgeBio’s Attruby approved for ATTR-CM, PTC’s gene therapy for AADC deficiency, and Gilead withdrew Trodelvy for urothelial cancer
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Nov 12, 2024
Finance
AZ’s China roller-coaster
With AstraZeneca’s valuation down $30B, could the stock be in for a rebound?
BioCentury | Nov 8, 2024
Finance
Neurogene draws $200M PIPE ahead of next week’s Rett syndrome data
In BioCentury’s Finance Report: Travere’s follow-on, CrossBridge’s seed round among few fundings during quiet election week
BioCentury | Oct 4, 2024
Product Development
I-SPY 2.2 is working. Why aren’t others replicating the design?
Initial data show the I-SPY 2.2 design can uncover less toxic neoadjuvant breast cancer therapies
BioCentury | Sep 12, 2024
Product Development
Clinical Report: AstraZeneca, Daiichi turn to precision medicine after OS miss for Dato-DXd
Plus: Results from Relay, Centessa, Viridian, Amgen and more
Items per page:
1 - 10 of 78